• Skye Bioscience opened enrollment for Cohort 2 of its CBeyond Part C Expansion study, escalating weekly IV dosing of obesity drug candidate nimacimab to 600 mg following a safety review.
• The decision followed favorable early safety findings from the first four participants in Cohort 1 at 400 mg, with no neuropsychiatric adverse events reported to date.
• Results have not been presented; the study is designed to generate preliminary safety and pharmacokinetic readouts at higher exposures, with data expected in the future.
• The expansion compares nimacimab monotherapy with placebo over 15 weeks, positioning the program to support further development of a peripherally acting CB1 approach in obesity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200700PRIMZONEFULLFEED9723654) on May 20, 2026, and is solely responsible for the information contained therein.